Stockreport

Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview

ACADIA Pharmaceuticals Inc.  (ACAD) 
Last acadia pharmaceuticals inc. earnings: 2/26 04:05 pm Check Earnings Report
PDF - 3Q24 total revenues of $250.4 million, up 18% year-over-year- 3Q24 NUPLAZID® (pimavanserin) net product sales of $159.2 million, up 10% year-over-year- 3Q24 DAYBUE™ (t [Read more]